Abstract
Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.
Similar content being viewed by others
References
Stupp R, Dietrich P-Y, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382
Stupp R, Mason WP, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996
Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266
Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710
DeAngelis LM (2001) Brain tumors. N Eng J Med 344:114–123
Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual data from 12 randomized trials. Lancet 359:1011–1018
de Wit MCY, de Bruin HG, Eijkenboom W, Sillevis-Smitt PAE, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535–537
Cross NE, Glantz MJ (2003) Neurologic complications of radiation therapy. In Wen PY, Glantz MJ (eds) Complications of Systemic Cancer. W.B. Saunders Co., Philadelphia, pp 249–277
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chamberlain, M.C., Glantz, M.J., Chalmers, L. et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82, 81–83 (2007). https://doi.org/10.1007/s11060-006-9241-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-006-9241-y